ID   KM641
AC   CVCL_D3P7
SY   KM-641
RX   Patent=EP0493686B1;
RX   PubMed=8439988;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-3116.
CC   Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the chimeric (mouse/human) ecromeximab (KM871) therapeutic antibody developed for the treatment of malignant melanoma.
CC   Monoclonal antibody isotype: IgG3, kappa.
CC   Monoclonal antibody target: ChEBI; CHEBI:89636; Ganglioside GD3.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_3412 ! P3X63Ag8U.1
CA   Hybridoma
DT   Created: 30-01-24; Last updated: 30-01-24; Version: 1
//
RX   Patent=EP0493686B1;
RA   Hanai N., Ohta S.;
RT   "Monoclonal antibodies to glycolipid carbohydrate chains.";
RL   Patent number EP0493686B1, 12-Feb-1991.
//
RX   PubMed=8439988; DOI=10.1007/BF01740908;
RA   Ohta S., Honda A., Tokutake Y., Yoshida H., Hanai N.;
RT   "Antitumor effects of a novel monoclonal antibody with high binding
RT   affinity to ganglioside GD3.";
RL   Cancer Immunol. Immunother. 36:260-266(1993).
//